RxDoctor Payments Data

Grady Hughes, MD

Ophthalmology · Seattle, WANPI 1790825313

Payments from drug & device makers

$767in general payments, 2019–2025

Across 28 payments — averaging $27.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$178
  • Carl Zeiss Meditec, Inc.$178
  • Alcon$129
  • Oyster Point Pharma, Inc.$63
  • Sun Pharmaceutical Industries Inc.$49
  • Coopervision Inc.$46
  • plus $123 from 5 others

What the payments were for

  • Food & beverage$74797%
  • Gifts$193%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$767 in reported general payments places this provider in the 45th percentile of 428 ophthalmology providers in Washington.

See all ophthalmology providers in Washington

Medicare billing

Part B allowed, 2024
$192,467
Medicare patients
716
Services billed
1,526

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine22$29,512
CombiganBrimonidine Tartrate/Timolol21$12,028
Fluorometholone107$8,441
LumiganBimatoprost12$7,043
Tobramycin-DexamethasoneTobramycin/Dexamethasone111$4,610
SimbrinzaBrinzolamide/Brimonidine Tart14$3,842
Latanoprost196$3,390
Prednisolone Acetate97$3,036
Travoprost12$2,028
Brimonidine Tartrate33$1,996
Loteprednol Etabonate12$1,397
Timolol Maleate66$1,284
Azelastine Hcl61$1,261
Ketorolac Tromethamine37$884
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat21$476

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan, Lumigan$178$48,58355 claims
AlconSimbrinza$129$3,84214 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$20$1,39712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 428 ophthalmology providers in Washington.

Other ophthalmology in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →